+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cardiac Marker Testing Market by Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Product (Instrument (Chemiluminescence, ELISA), Reagents & Kits), Disease (MI, CHF, Atherosclerosis), User, ASP & Buying Criteria - Global Forecast to 2028

  • PDF Icon

    Report

  • 216 Pages
  • October 2023
  • Region: Global
  • Markets and Markets
  • ID: 5669901

Laboratory Testing Facilities Segment Accounted for Largest Share of North American Market in 2022

The global cardiac marker testing market is projected to reach USD 6.9 billion by 2028 from USD 4.1 billion in 2022, growing at a CAGR of 9.4% during the forecast period. The projected surge in market growth for cardiac marker testing is underpinned by a confluence of compelling advantages. Notably, cardiac marker testing is driven by aging population, rising cases of cardiovascular diseases, increase in research & funding initiatives from public/private organizations to discover novel cardiac biomarkers. Furthermore, the escalating early detection of heart failure diseases with improved efficacy for diagnosing heart conditions amplifies the demand for advanced treatment modalities, with cardiac marker testing positioned as a forefront solution. This convergence of factors is poised to usher in a phase of robust expansion within the market, consequently shaping the landscape of cardiac marker testing adoption in the forthcoming forecasting years.

Troponin I and T segment to register largest market share in 2022-2028

Based on the biomarker type, cardiac marker testing market is segmented into Troponin I and T, Creatine Kinase-MB (CK-MB), Brain Natriuretic Peptide (BNP and NT-PROBNP), Myoglobin, High-sensitivity C-reactive Protein (hs-CRP), and other cardiac biomarkers. The Troponin I and T segment register a largest market share over the forecast period of 2022-2028. The growth of this segment is propelled by factors such as exceptional sensitivity and specificity, prolonged elevation duration (with levels rising over 4-8 hours, peaking at 10-24 hours, and declining over ten days), and the swift prediction of outcomes. Moreover, lab technicians are more adept at utilizing these markers in comparison to other biomarkers, further fueling the segment's advancement.

Laboratory testing facilities segment held the largest share of cardiac marker testing market in 2022, by End-user.

Based on the end-user, the cardiac marker testing market is segmented into laboratory testing facilities, academic institutes, and point-of-care testing facilities. In 2022, the laboratory testing facilities segment accounted for the largest share of 61.2% of the global cardiac marker testing market. The growth of this segment is being propelled by factors including increased testing efficiency, superior sensitivity and diagnostic precision in comparison to point-of-care testing, and a strong preference for laboratory testing over point-of-care testing.

Asia Pacific to register significant growth rate in the market during the forecast period.

For the forecasting period 2023-2028, the APAC region is expected to register a significant growth rate in the market during the forecast period. Asia Pacific comprises India, China, Japan, Australia, South Korea, and RoAPAC. The Asia-Pacific (APAC) region has witnessed a significant increase in the market growth rate for cardiac marker testing. There are several drivers that contributed to this growth:

The Asia Pacific market is experiencing growth due to increased investments by government agencies in emerging countries, aimed at enhancing healthcare infrastructure. Additionally, the market is benefiting from the rise in independent clinical laboratories, a substantial patient population, and strategic initiatives by industry players to expand their offerings of cardiac testing products in the Asia Pacific region.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-43%, Tier 2-30%, and Tier 3- 27%
  • By Designation: C-level-10%, Director-level-15%, and Others-75%
  • By Region: North America-40%, Europe-30%, Asia Pacific-23%, Latin America-5%, and the Middle East & Africa-2%

Prominent players in this market are F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), ), Thermo Fisher Scientific Inc. (US) among others.

Research Coverage

  • The report studies the marker testing market based on products, biomarker type, diseases, end user, and region.
  • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. 
  • The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
  • The report studies micro markets with respect to their growth trends, prospects, and contributions to the global cardiac marker testing market 
  • The report forecasts the revenue of market segments with respect to five major regions.

Key Benefits of Buying the Report:

The report will help the new entrants/ market leaders/smaller firms in this market with investment evaluation viability within the cardiac marker testing market through a thorough analysis of comprehensive data, thereby facilitating robust risk assessment and enabling well-informed investment determinations. Benefit from meticulous market segmentation encompassing application, end-user, and regional dimensions, affording tailored insights for precise segment targeting. The report also provides an all-encompassing evaluation of encapsulating pivotal trends, challenges, growth catalysts and prospects, thereby empowering strategic decision-making with astute discernment. 

The report provides insights on the following pointers: 

  • Analysis of key drivers (increasing prevalence of cardiovascular diseases, Increasing geriatric population and subsequent rise in heart conditions worldwide, Ongoing clinical trials for the identification of novel cardiac biomarkers), restraints (Technical issues related to sample collection & storage, Unfavorable regulatory processes and limited reimbursement structure), opportunities (Point-of-care testing (POCT) with cardiac biomarkers, Emerging markets offers high-growth opportunities, Ongoing research on novel cardiac biomarkers for cardiovascular diseases), and challenges (Challenges associated with biomarker assay validation) influencing the growth of the cardiac marker testing market 
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the cardiac marker testing market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the cardiac marker testing market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cardiac marker testing market 
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), among others.

Table of Contents

1 Introduction
1.1 Study Objectives
1.2 Market Definition
1.2.1 Inclusions and Exclusions of Study
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Regions Covered
1.4 Years Considered
1.5 Currency
1.6 Research Limitations
1.7 Market Stakeholders
1.8 Summary of Changes
1.8.1 Recession Impact

2 Research Methodology
2.1 Research Data
2.2 Research Design
2.2.1 Secondary Research
Figure 1 Key Data from Secondary Sources
2.2.2 Primary Research
2.2.2.1 Primary Sources
2.2.2.2 Key Industry Insights
2.2.2.3 Breakdown of Primaries
Figure 2 Breakdown of Primary Interviews: Supply-Side and Demand-Side Participants
Figure 3 Breakdown of Primary Interviews: by Company Type, Designation, and Region
2.3 Market Size Estimation
Figure 4 Research Methodology: Hypothesis Building
2.3.1 Bottom-Up Approach
2.3.2 Approach 1: Company Revenue Estimation Approach
Figure 5 Cardiac Marker Testing Market Size Estimation: Approach 1 (Company Revenue Estimation)
2.3.3 Approach 2: Customer-Based Market Estimation
Figure 6 Cardiac Marker Testing Market Size Estimation: Bottom-Up Approach
2.3.4 Approach 3: Top-Down Approach
2.3.5 Approach 4: Primary Interviews
Figure 7 Cardiac Marker Testing Market Size Estimation: Top-Down Approach
2.4 Data Triangulation and Market Breakdown
Figure 8 Data Triangulation Methodology
2.5 Market Share Assessment
2.6 Study Assumptions
2.7 Risk Assessment
Table 1 Limitations and Associated Risks
2.8 Growth Rate Assumptions
2.9 Recession Impact

3 Executive Summary
Figure 9 Cardiac Marker Testing Market, by Biomarker Type, 2023 Vs. 2028 (USD Million)
Figure 10 Cardiac Marker Testing Market, by Product, 2023 Vs. 2028 (USD Million)
Figure 11 Cardiac Marker Testing Market, by Indication, 2023 Vs. 2028 (USD Million)
Figure 12 Cardiac Marker Testing Market, by End-user, 2023 Vs. 2028 (USD Million)
Figure 13 Geographical Snapshot of Cardiac Marker Testing Market

4 Premium Insights
4.1 Cardiac Marker Testing Market Overview
Figure 14 Rising Prevalence of Cardiovascular Diseases to Drive Market
4.2 North America: Cardiac Marker Testing Market, by Country and End-user, 2022
Figure 15 Laboratory Testing Facilities Segment Accounted for Largest Share of North American Market in 2022
4.3 Cardiac Marker Testing Market: Regional Mix
Figure 16 North America Will Continue to Dominate Market During Forecast Period
4.4 Cardiac Marker Testing Market: Geographic Growth Opportunities
Figure 17 China to Register Highest Growth During Forecast Period

5 Market Overview
5.1 Introduction
Figure 18 Cardiac Marker Testing Market: Drivers, Restraints, Opportunities, and Challenges
5.1.1 Drivers
5.1.1.1 Rising Prevalence of Cardiovascular Diseases
5.1.1.2 Increasing Geriatric Population and Subsequent Rise in Heart Conditions Worldwide
5.1.1.3 Growing Research and Funding Initiatives from Public and Private Organizations
5.1.1.4 Rising Clinical Studies for Identification of Novel Cardiac Biomarkers
5.1.2 Restraints
5.1.2.1 Technical Issues Related to Sample Collection and Storage
5.1.2.2 Unfavorable Regulatory Processes and Limited Reimbursement Structure
5.1.3 Opportunities
5.1.3.1 Point-Of-Care Testing with Cardiac Biomarkers
5.1.3.2 Ongoing Research on Novel Cardiac Biomarkers for Cardiovascular Diseases
5.1.3.3 Emerging Markets
5.1.4 Challenges
5.1.4.1 Challenges Associated with Biomarker Assay Validation
5.2 Key Stakeholders and Buying Criteria
5.2.1 Key Stakeholders in Buying Process
Figure 19 Influence of Stakeholders on Buying Process for Cardiac Marker Testing Market
Table 2 Influence of Stakeholders on Buying Process for Key Product Segments (%)
5.3 Porter's Five Forces Analysis
Table 3 Cardiac Marker Testing Market: Porter's Five Forces Analysis
5.3.1 Threat of New Entrants
5.3.2 Threat of Substitutes
5.3.3 Bargaining Power of Suppliers
5.3.4 Bargaining Power of Buyers
5.3.5 Intensity of Competitive Rivalry
5.4 Regulatory Analysis
5.4.1 US
Table 4 Us: Medical Device Regulatory Approval Process
5.4.2 Europe
Table 5 Europe: Classification of Ivd Devices
5.4.3 Japan
Table 6 Japan: Classification of Ivd Reagents
Table 7 Japan: Time, Cost, and Complexity of Registration Process
5.5 Reimbursement Scenario
Table 8 Reimbursement Codes for Various Biomarkers
5.6 Ecosystem Mapping
5.7 Value Chain Analysis
5.7.1 Research & Development
5.7.2 Procurement and Product Development
5.7.3 Marketing, Sales and Distribution, and Post-Sales Services
Figure 20 Value Chain Analysis of Cardiac Marker Testing Market
5.8 Supply Chain Analysis
5.8.1 Prominent Companies
5.8.2 Small & Medium-Sized Companies
5.8.3 End-users
Figure 21 Supply Chain Analysis of Cardiac Marker Testing Market
5.9 Pricing Analysis
Table 9 Average Selling Price of Cardiac Biomarker Troponin I and T Test Kits, 2021
Table 10 Average Selling Price of Cardiac Biomarker Bpn and Nt-Probnp Test Kits, 2021
Table 11 Average Selling Price of Cardiac Biomarker Myoglobin Test Kits, 2021
Table 12 Average Selling Price of Cardiac Biomarker Ck-Mb Test Kits, 2022
Table 13 Average Selling Price of Cardiac Biomarker C-Reactive Protein (Hs-Crp) Test Kits, 2022
Table 14 Average Selling Price Trend of Cardiac Marker Test Kits, by Country, 2021-2023 (USD)
5.10 Patent Analysis
Figure 22 Top 10 Patent Applicants for Cardiac Marker Testing, January 2012-September 2022
Figure 23 Top 10 Patent Owners for Cardiac Marker Testing, January 2012-September 2022
5.11 Trade Analysis
Table 15 Import Data for Cardiac Marker Testing (Hs Code 3822), by Country, 2018-2022 (USD Thousand)
Table 16 Export Data for Cardiac Marker Testing (Hs Code 3822), by Country, 2018-2022 (USD Thousand)
5.12 Case Studies
Table 17 Case Study: Breakthrough in Acute Myocardial Infarction Diagnosis with High-Sensitivity Troponin I Assays
5.13 Key Conferences and Events, 2023-2024
Table 18 Cardiac Marker Testing Market: Detailed List of Key Conferences and Events in 2023-2024
5.14 Trends/Disruptions Impacting Customer's Business
Figure 24 Emerging Trends and Opportunities Affecting Future Revenue Mix
5.15 Impact of Recession on Cardiac Marker Testing Market

6 Cardiac Marker Testing Market, by Product
6.1 Introduction
Table 19 Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
6.2 Reagents & Kits
6.2.1 Rising Volume of Diagnostic Tests to Drive Demand
Table 20 Cardiac Marker Testing Reagents & Kits Market, by Biomarker Type, 2021-2028 (USD Million)
Table 21 Cardiac Marker Testing Reagents & Kits Market, by Region, 2021-2028 (USD Million)
6.3 Instruments
Table 22 Cardiac Marker Testing Instruments Market, by Technique, 2021-2028 (USD Million)
Table 23 Cardiac Marker Testing Instruments Market, by Biomarker Type, 2021-2028 (USD Million)
Table 24 Cardiac Marker Testing Instruments Market, by Region, 2021-2028 (USD Million)
6.3.1 Chemiluminescence
6.3.1.1 Most Preferred Method for Quantifying Cardiac Biomarkers
Table 25 Chemiluminescence Instruments Market, by Biomarker Type, 2021-2028 (USD Million)
Table 26 Chemiluminescence Instruments Market, by Region, 2021-2028 (USD Million)
6.3.2 Immunofluorescence
6.3.2.1 Demand for Stable and Safer Reagents to Support Market Growth
Table 27 Immunofluorescence Instruments Market, by Biomarker Type, 2021-2028 (USD Million)
Table 28 Immunofluorescence Instruments Market, by Region, 2021-2028 (USD Million)
6.3.3 Elisa
6.3.3.1 Long Shelf Life and Ease of Use to Propel Growth
Table 29 Elisa Instruments Market, by Biomarker Type, 2021-2028 (USD Million)
Table 30 Elisa Instruments Market, by Region, 2021-2028 (USD Million)
6.3.4 Immunochromatography
6.3.4.1 Increasing Use in Point-Of-Care Settings to Propel Adoption
Table 31 Immunochromatography Instruments Market, by Biomarker Type, 2021-2028 (USD Million)
Table 32 Immunochromatography Instruments Market, by Region, 2021-2028 (USD Million)

7 Cardiac Marker Testing Market, by Indication
7.1 Introduction
Table 33 Cardiac Marker Testing Market, by Indication, 2021-2028 (USD Million)
7.2 Myocardial Infarction
7.2.1 Availability of High-Sensitivity Biomarkers for Detection to Drive Market
Table 34 Cardiac Marker Testing Market for Myocardial Infarction, by Region, 2021-2028 (USD Million)
7.3 Congestive Heart Failure
7.3.1 Increasing Use of Multimarker Testing to Support Market Growth
Table 35 Cardiac Marker Testing Market for Congestive Heart Failure, by Region, 2021-2028 (USD Million)
7.4 Acute Coronary Syndrome
7.4.1 Increasing Incidence of Risk Factors Associated with Acs to Drive Adoption of Cardiac Markers
Table 36 Cardiac Marker Testing Market for Acute Coronary Syndrome, by Region, 2021-2028 (USD Million)
7.5 Atherosclerosis
7.5.1 High Prevalence of Atherosclerosis to Drive Market
Table 37 Cardiac Marker Testing Market for Atherosclerosis, by Region, 2021-2028 (USD Million)
7.6 Ischemia
7.6.1 Increase in Cardiac Ischemia to Boost Demand for Cardiac Marker Tests
Table 38 Cardiac Marker Testing Market for Ischemia, by Region, 2021-2028 (USD Million)

8 Cardiac Marker Testing Market, by Biomarker Type
8.1 Introduction
Table 39 Cardiac Marker Testing Market, by Biomarker Type, 2021-2028 (USD Million)
8.2 Troponin I and T
8.2.1 High Sensitivity and Specificity in Detection of Cvd to Drive Market
Table 40 Troponin I and T Cardiac Marker Testing Market, by Indication, 2021-2028 (USD Million)
Table 41 Troponin I and T Cardiac Marker Testing Market, by End-user, 2021-2028 (USD Million)
Table 42 Troponin I and T Cardiac Marker Testing Market, by Region, 2021-2028 (USD Million)
8.3 Creatine Kinase-Mb
8.3.1 Poor Specificity and Brief Elevation Duration to Hamper Market Growth
Table 43 Creatine Kinase-Mb Cardiac Marker Testing Market, by Indication, 2021-2028 (USD Million)
Table 44 Creatine Kinase-Mb Cardiac Marker Testing Market, by End-user, 2021-2028 (USD Million)
Table 45 Creatine Kinase-Mb Cardiac Marker Testing Market, by Region, 2021-2028 (USD Million)
8.4 Brain Natriuretic Peptide
8.4.1 Use of Bnp with Other Cardiac Markers to Enhance Utilization
Table 46 Cardiac Marker Testing Market for Brain Natriuretic Peptide (Bnp and Nt-Probnp), by Indication, 2021-2028 (USD Million)
Table 47 Cardiac Marker Testing Market for Brain Natriuretic Peptide (Bnp and Nt-Probnp), by End-user, 2021-2028 (USD Million)
Table 48 Cardiac Marker Testing Market for Brain Natriuretic Peptide (Bnp and Nt-Probnp), by Region, 2021-2028 (USD Million)
8.5 Myoglobin
8.5.1 Used to Assess Patients with Chest Pain in Emergency Department Settings
Table 49 Cardiac Marker Testing Market for Myoglobin, by Indication, 2021-2028 (USD Million)
Table 50 Cardiac Marker Testing Market for Myoglobin, by End-user, 2021-2028 (USD Million)
Table 51 Cardiac Marker Testing Market for Myoglobin, by Region, 2021-2028 (USD Million)
8.6 High-Sensitivity C-Reactive Protein
8.6.1 Increasing Incidence of Cardiovascular Diseases to Propel Adoption
Table 52 Cardiac Marker Testing Market for High-Sensitivity C-Reactive Protein, by Indication, 2021-2028 (USD Million)
Table 53 Cardiac Marker Testing Market for High-Sensitivity C-Reactive Protein, by End-user, 2021-2028 (USD Million)
Table 54 Cardiac Marker Testing Market for High-Sensitivity C-Reactive Protein, by Region, 2021-2028 (USD Million)
8.7 Other Cardiac Biomarkers
Table 55 Other Cardiac Biomarkers Market, by Indication, 2021-2028 (USD Million)
Table 56 Other Cardiac Biomarkers Market, by End-user, 2021-2028 (USD Million)
Table 57 Other Cardiac Biomarkers Market, by Region, 2021-2028 (USD Million)

9 Cardiac Marker Testing Market, by End-user
9.1 Introduction
Table 58 Cardiac Marker Testing Market, by End-user, 2021-2028 (USD Million)
9.2 Laboratory Testing Facilities
Table 59 Cardiac Marker Testing Market for Laboratory Testing Facilities, by Type, 2021-2028 (USD Million)
Table 60 Cardiac Marker Testing Market for Laboratory Testing Facilities, by Region, 2021-2028 (USD Million)
9.2.1 Hospital Laboratories
9.2.1.1 Early Diagnosis Associated with In-House Labs to Support Market Growth
Table 61 Cardiac Marker Testing Market for Hospital Laboratories, by Region, 2021-2028 (USD Million)
9.2.2 Reference Laboratories
9.2.2.1 Affordable and Time-Efficient Services Associated with Reference Laboratories to Drive Market
Table 62 Cardiac Marker Testing Market for Reference Laboratories, by Region, 2021-2028 (USD Million)
9.2.3 Contract Testing Laboratories
9.2.3.1 Ability to Perform Multiple Tests to Propel Market
Table 63 Cardiac Marker Testing Market for Contract Testing Laboratories, by Region, 2021-2028 (USD Million)
9.3 Academic Institutes
9.3.1 Continuous Research & Development of Novel Biomarkers to Drive Market
Table 64 Cardiac Marker Testing Market for Academic Institutes, by Region, 2021-2028 (USD Million)
9.4 Point-Of-Care Testing Facilities
9.4.1 Early Detection and Lower Turnaround Time to Propel Market
Table 65 Cardiac Marker Testing Market for Point-Of-Care Testing Facilities, by Region, 2021-2028 (USD Million)

10 Cardiac Marker Testing Market, by Region
10.1 Introduction
Table 66 Cardiac Marker Testing Market, by Region, 2021-2028 (USD Million)
10.2 North America
10.2.1 North America: Recession Impact
Figure 25 North America: Cardiac Marker Testing Market Snapshot
Table 67 North America: Cardiac Marker Testing Market, by Country, 2021-2028 (USD Million)
Table 68 North America: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
Table 69 North America: Cardiac Marker Testing Instruments Market, by Technique, 2021-2028 (USD Million)
Table 70 North America: Cardiac Marker Testing Market, by Biomarker Type, 2021-2028 (USD Million)
Table 71 North America: Cardiac Marker Testing Market, by End-user, 2021-2028 (USD Million)
10.2.2 US
10.2.2.1 Growing Support from Nih for Development of Novel Cardiac Biomarkers to Drive Market
Table 72 Us: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.2.3 Canada
10.2.3.1 Government Initiatives to Support Market Growth
Table 73 Canada: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.3 Europe
10.3.1 Europe: Recession Impact
Table 74 Europe: Cardiac Marker Testing Market, by Country, 2021-2028 (USD Million)
Table 75 Europe: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
Table 76 Europe: Cardiac Marker Testing Instruments Market, by Technique, 2021-2028 (USD Million)
Table 77 Europe: Cardiac Marker Testing Market, by Biomarker Type, 2021-2028 (USD Million)
Table 78 Europe: Cardiac Marker Testing Market, by End-user, 2021-2028 (USD Million)
10.3.2 Germany
10.3.2.1 Favorable Government Policies to Support Market Growth
Table 79 Germany: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.3.3 France
10.3.3.1 Rising Geriatric Population to Drive Market
Table 80 France: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.3.4 UK
10.3.4.1 Government Initiatives to Boost Adoption of Cardiac Biomarkers
Table 81 Uk: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.3.5 Italy
10.3.5.1 Adoption of Advanced Diagnostic Technologies to Drive Market
Table 82 Italy: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.3.6 Spain
10.3.6.1 Establishment of Large and Advanced Laboratories to Drive Uptake of Cardiac Marker Testing
Table 83 Spain: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.3.7 Rest of Europe
Table 84 Rest of Europe: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.4 Asia-Pacific
10.4.1 Asia-Pacific: Recession Impact
Figure 26 Asia-Pacific: Cardiac Marker Testing Market Snapshot
Table 85 Asia-Pacific: Cardiac Marker Testing Market, by Country, 2021-2028 (USD Million)
Table 86 Asia-Pacific: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
Table 87 Asia-Pacific: Cardiac Marker Testing Instruments Market, by Technique, 2021-2028 (USD Million)
Table 88 Asia-Pacific: Cardiac Marker Testing Market, by Biomarker Type, 2021-2028 (USD Million)
Table 89 Asia-Pacific: Cardiac Marker Testing Market, by End-user, 2021-2028 (USD Million)
10.4.2 Japan
10.4.2.1 Presence of Advanced Laboratory Facilities to Drive Market
Table 90 Japan: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.4.3 China
10.4.3.1 Growing Number of Independent Clinical Laboratories to Drive Demand for Cardiac Markers
Table 91 China: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.4.4 India
10.4.4.1 Presence of Large Patient Population to Drive Demand
Table 92 India: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.4.5 Australia
10.4.5.1 Increasing Healthcare Expenditure to Support Market Growth
Table 93 Australia: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.4.6 South Korea
10.4.6.1 Growing Number of Private Hospitals to Drive Adoption of Advanced Testing Services
Table 94 South Korea: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.4.7 Rest of Asia-Pacific
Table 95 Rest of Asia-Pacific: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.5 Latin America
10.5.1 Latin America: Recession Impact
Table 96 Latin America: Cardiac Marker Testing Market, by Country, 2021-2028 (USD Million)
Table 97 Latin America: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
Table 98 Latin America: Cardiac Marker Testing Instruments Market, by Technique, 2021-2028 (USD Million)
Table 99 Latin America: Cardiac Marker Testing Market, by Biomarker Type, 2021-2028 (USD Million)
Table 100 Latin America: Cardiac Marker Testing Market, by End-user, 2021-2028 (USD Million)
10.5.2 Brazil
10.5.2.1 Increasing Government Support for Advancements in Healthcare to Support Market Growth
Table 101 Brazil: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.5.3 Mexico
10.5.3.1 Rising Demand for Technologically Advanced Products to Drive Uptake of Cardiac Markers
Table 102 Mexico: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.5.4 Rest of Latin America
Table 103 Rest of Latin America: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
10.6 Middle East & Africa
10.6.1 Improvements in Healthcare Infrastructure to Drive Demand for Advanced Markers
10.6.2 Middle East & Africa: Recession Impact
Table 104 Middle East & Africa: Cardiac Marker Testing Market, by Product, 2021-2028 (USD Million)
Table 105 Middle East & Africa: Cardiac Marker Testing Instruments Market, by Technique, 2021-2028 (USD Million)
Table 106 Middle East & Africa: Cardiac Marker Testing Market, by Biomarker Type, 2021-2028 (USD Million)
Table 107 Middle East & Africa: Cardiac Marker Testing Market, by End-user, 2021-2028 (USD Million)
10.6.3 Gcc Countries

11 Competitive Landscape
11.1 Overview
11.2 Strategies Adopted by Key Players
11.2.1 Overview of Strategies Adopted by Players in Cardiac Marker Testing Market
11.3 Revenue Share Analysis
Figure 27 Revenue Share Analysis of Top Players in Cardiac Marker Testing Market, 2018-2022 (USD Million)
11.4 Market Ranking Analysis
11.5 Company Evaluation Matrix
11.5.1 Stars
11.5.2 Emerging Leaders
11.5.3 Pervasive Players
11.5.4 Participants
Figure 29 Cardiac Marker Testing Market: Company Evaluation Matrix, 2022
11.6 Startup/Sme Evaluation Matrix
11.6.1 Progressive Companies
11.6.2 Starting Blocks
11.6.3 Responsive Companies
11.6.4 Dynamic Companies
Figure 30 Cardiac Marker Testing Market: Startup/Sme Evaluation Matrix, 2022
11.7 Company Footprint
Table 108 Product and Regional Footprint Analysis of Top Players in Cardiac Marker Testing Market
Table 109 Product Footprint Analysis of Top Players in Cardiac Marker Testing Market
Table 110 Regional Footprint Analysis of Top Players in Cardiac Marker Testing Market
11.8 Competitive Scenarios and Trends
Table 111 Key Product Launches
Table 112 Key Deals
Table 113 Other Key Developments

12 Company Profiles
12.1 Key Players
(Business Overview, Products Offered, Recent Developments, and Analyst's View (Key Strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 F. Hoffmann-La Roche AG
Table 114 F. Hoffmann-La Roche Ag: Company Overview
Figure 31 F. Hoffmann-La Roche Ag: Company Snapshot (2022)
12.1.2 Abbott Laboratories
Table 115 Abbott Laboratories: Company Overview
Figure 32 Abbott Laboratories: Company Snapshot (2022)
12.1.3 Siemens Healthineers AG
Table 116 Siemens Healthineers Ag: Company Overview
Figure 33 Siemens Healthineers Ag: Company Snapshot (2022)
12.1.4 Danaher Corporation
Table 117 Danaher Corporation: Company Overview
Figure 34 Danaher Corporation: Company Snapshot (2022)
12.1.5 Bio-Rad Laboratories, Inc.
Table 118 Bio-Rad Laboratories, Inc.: Company Overview
Figure 35 Bio-Rad Laboratories, Inc.: Company Snapshot (2022)
12.1.6 Biomérieux Sa
Table 119 Biomérieux Sa: Company Overview
Figure 36 Biomérieux Sa: Company Snapshot (2022)
12.1.7 Becton, Dickinson and Company
Table 120 Becton, Dickinson and Company: Company Overview
Figure 37 Becton, Dickinson and Company: Company Snapshot (2022)
12.1.8 Thermo Fisher Scientific Inc.
Table 121 Thermo Fisher Scientific Inc.: Company Overview
Figure 38 Thermo Fisher Scientific Inc.: Company Snapshot (2022)
12.1.9 Diasorin S.P.A.
Table 122 Diasorin S.P.A.: Company Overview
Figure 39 Diasorin S.P.A.: Company Snapshot (2022)
12.1.10 Perkinelmer Inc.
Table 123 Perkinelmer Inc.: Company Overview
Figure 40 Perkinelmer Inc.: Company Snapshot (2022)
12.1.11 Tosoh Corporation
Table 124 Tosoh Corporation: Company Overview
Figure 41 Tosoh Corporation: Company Snapshot (2023)
12.1.12 Lsi Medience Corporation (Phc Holdings Corporation)
Table 125 Lsi Medience Corporation: Company Overview
Figure 42 Phc Holdings Corporation: Company Snapshot (2022)
12.1.13 Quidel Corporation
Table 126 Quidel Corporation: Company Overview
Figure 43 Quidel Corporation: Company Snapshot (2022)
12.1.14 Randox Laboratories
Table 127 Randox Laboratories: Company Overview
12.1.15 Guangzhou Wondfo Biotech Co. Ltd.
Table 128 Guangzhou Wondfo Biotech Co. Ltd.: Business Overview
12.1.16 Boditech Med Inc.
Table 129 Boditech Med Inc.: Business Overview
12.1.17 Tulip Diagnostics (P) Ltd.
Table 130 Tulip Diagnostics (P) Ltd.: Business Overview
12.1.18 Btnx Inc.
Table 131 Btnx Inc.: Business Overview
12.1.19 Response Biomedical
Table 132 Response Biomedical: Business Overview
12.1.20 Alfa Scientific Designs, Inc.
Table 133 Alfa Scientific Designs, Inc.: Business Overview
12.2 Other Players
12.2.1 Ctk Biotech, Inc.
12.2.2 Creative Diagnostics
12.2.3 Lifesign LLC
12.2.4 Cardiogenics Holdings Inc.
12.2.5 Atlas Medical GmbH
*Details on Business Overview, Products Offered, Recent Developments, and Analyst's View (Key Strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) Might Not be Captured in Case of Unlisted Companies.

13 Appendix
13.1 Discussion Guide
13.2 Knowledgestore: Subscription Portal
13.3 Customization Options
13.4 Related Reports
13.5 Author Details

Executive Summary

Companies Mentioned

  • Abbott Laboratories
  • Alfa Scientific Designs, Inc.
  • Atlas Medical GmbH
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomérieux Sa
  • Boditech Med Inc.
  • Btnx Inc.
  • Cardiogenics Holdings Inc.
  • Creative Diagnostics
  • Ctk Biotech, Inc.
  • Danaher Corporation
  • Diasorin S.P.A.
  • F. Hoffmann-La Roche AG
  • Guangzhou Wondfo Biotech Co. Ltd.
  • Lifesign LLC
  • Lsi Medience Corporation (Phc Holdings Corporation)
  • Perkinelmer Inc.
  • Quidel Corporation
  • Randox Laboratories
  • Response Biomedical
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Tosoh Corporation
  • Tulip Diagnostics (P) Ltd.

Methodology

Loading
LOADING...

Table Information